	Discovery	Lead Opt.	Preclinical	Phase 1	Phase 2	Phase 3
MBX-400 (filociclovir)	*Novel nucleoside analog dual DNA polymerase/kinase inhibitor*					
	Adenoviral respiratory infections – Pandemic Preparedness					
	Cytomegalovirus-related infections in transplant recipients					
	Adenoviral conjunctivitis					
Priority Pathogen Programs	*Non-traditional/novel mechanisms targeting CDC/WHO Priority Pathogens*					
	Pseudomonas Type III Secretion System (virulence) **Pneumonia (VAP; intubated HAP/CAP)**					
	Trans-translation (Broad spectrum G+/G-) **MDR Gonorrhoeae**					
	Efflux pump inhibitors **Pathogenic Enterobacteriaceae/CRE**					
Public Health	*Urgent public health needs*					
	MDR/XDR Tuberculosis					
	Malaria Ebola Virus					

Powered by CARB-X | AMR CENTRE – The UK R&D Centre for Antimicrobial Resistance | NIH National Institute of Allergy and Infectious Diseases

Powered by CARB-X | AMR CENTRE – The UK R&D Centre for Antimicrobial Resistance | NIH National Institute of Allergy and Infectious Diseases | Department of Defense, United States of America

NIH National Institute of Allergy and Infectious Diseases

NIH National Institute of Allergy and Infectious Diseases | Department of Defense, United States of America